Gary Schiltz

Finally, in tumor models of MLL-r leukemia, our lead degrader (DOT1L808) shows profound anti-tumor efficacy, supporting this approach as a potential new therapeutic option for leukemia. # @NUChemistry @LurieCancer pubs.acs.org/doi/10.1021/ac…

Here, we show the development of highly potent DOT1L degraders (DC50 = 5 nM) that are exquisitely selective for DOT1L and show selective anti-proliferative effects in MLL-r cancer cells. Notably, our degraders are also equally potent in menin-inhibitor-resistant cells.

Excited to share a new publication in collaboration with Dr. @SarkiAbdulkadi1 . We developed new degraders for histone methyltransferase DOT1L. DOT1L plays a key role in the progression of leukemias with MLL-rearrangements, and while DOT1L inhibitors have been studied...

The chemistry was led by the amazing Dr. Atul Jain. aacrjournals.org/mct/article-ab…

Happy to share a new publication with @LeonidasPlatan1 and @LurieCancer where we identified new inhibitors of the mTORC2-specific protein SIN1. These represent novel mTORC2 chemical probes while possessing intriguing anti-cancer activity against leukemia and other cancers.

Now online: Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies doi.org/10.1158/1535-7…

Thanks @drughunter_com for highlighting ours and others' work on IDO1. Recent advances suggest going beyond inhibiting IDO1 enzyme activity to effectively target this maladaptive factor in cancer. We couldn't agree more: drughunter.com/commentary/dio… @GaryESchiltz @taykoch07 @sitcancer

Excited to be working on this project with you. Our demonstration that EZH2 degradation can be superior to inhibition in a prostate cancer tumor model lays an important foundation for further studies.

Delighted to share our recently published work on the role of DDX41 in resolving G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death. rdcu.be/ezlGS @NatureComms

ILLINOIS PRESIDENTS CUP CHAMPIONS ‼️🏆🏆🏆🏆🏆🏆🏆🏆 Congratulations to Coach Kieran & the 2011 GIRLS GA-R team who were crowned the U14 Illinois Presidents Cup Champions after a thrilling 2-1 OT victory over North Shore Elite! 💪🔥 These girls left it all on the field and earned their spot at the Presidents Cup Regional Tournament in St. Louis the week of June 13 — with a shot at the USYS National Presidents Cup‼️🌟⚽️ Goals scored by: Ericson ⚽️ Sargautis ⚽️ Let’s go, girls!! 💙 #PresidentsCupChampions #NextStopRegionals #BlueNation #WeAreGalaxy #thefutureisbright⭐️ @ILYOUTHSOCCER @USYouthSoccer

Pleased to share new work describing the most potent human IDO1 PROTAC to-date with a DC50 of 4.5nM: biorxiv.org/content/10.110… To learn more, please visit: linkedin.com/feed/update/ur… @GaryESchiltz @AACR @CancerResearch @sitcancer @LijieZhai @PrashantBommi @taykoch07 @ACS_Research

In this episode of our #BreakthroughsPodcast, @SarkiAbdulkadi1 discusses the discovery of compounds that block the 'undruggable' MYC gene, making #ProstateCancer tumors sensitive to hormone therapy. 🔗 spr.ly/6019o8Iml

Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma: pubmed.ncbi.nlm.nih.gov/38600951/ @theNCI @theABTA @gliomalab @TheresaWalunas @GaryESchiltz @NIH @NIHAging @NIH_NINDS @NeuroOnc @ACS_Research @gbmfoundation @myCARG @AACR @CancerResearch @ManonCampillo

@dwainwright_PhD @NUFeinbergMed @TheresaWalunas @NeuroOnc @gliomalab @theABTA @EPower9 @mirikim0 @myCARG @theNCI Congratulations Erik, Derek, and everyone involved in this work.

Congrats to M4 @NUFeinbergMed student, Erik Rabin, for his new publication, 'Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma'. sciencedirect.com/science/articl… @TheresaWalunas @GaryESchiltz @NeuroOnc @gliomalab @theABTA @EPower9 @mirikim0 @myCARG @theNCI

@dwainwright_PhD @LoyolaChicago @CancerResearch @sitcancer @theNCI @NIH @NeuroOnc @myCARG Congratulations, Derek! So well-deserved.

Today I received the official notice from the Provost @LoyolaChicago that my application for tenure has been approved. Very #grateful to everyone for their support!!! :) @CancerResearch @sitcancer @theNCI @NIH @NeuroOnc @myCARG

@dwainwright_PhD @koolmolecule @CancerResearch @sitcancer @LoyolaMedMD @LoyolaHealth That's awesome. Can't wait to talk next week and hear more.

Thanks Dr. ⁦@koolmolecule⁩ for update on radical new approach to inhibiting IDO1 in glioblastoma. There’s much to talk about with Dr. ⁦@GaryESchiltz⁩ in our meeting next week! ⁦@CancerResearch⁩ ⁦@sitcancer⁩ ⁦@LoyolaMedMD⁩ ⁦@LoyolaHealth⁩

@dwainwright_PhD @CCR_AACR @theNCI @NIHAging @CancerResearch @sitcancer @NeuroOnc @EANOassociation @TheresaWalunas @CraigHorbinski @KatyMccortney @NatureAging @AgingCell This is amazing and highly impactful work from your lab, Derek. Honored to play a small role in this. Can't wait to see what new discoveries you make in this area.

Excited to share new publication on Aging, Immunotherapy, and Glioblastoma published by @CCR_AACR :pubmed.ncbi.nlm.nih.gov/37725593/ @theNCI @NIHAging @CancerResearch @sitcancer @NeuroOnc @EANOassociation @GaryESchiltz @TheresaWalunas @CraigHorbinski @KatyMccortney @NatureAging @AgingCell

I am hiring 1-2 postdocs in #medicinalchemistry to work on #PROTAC and inhibitor projects as part of highly interdisciplinary collaborations with biologists and others. Please send a CV to apply to scheidt-ofc@northwestern.edu to apply.